×
About 1,128 results

ALLMedicine™ Indolent Lymphoma Center

Research & Reviews  244 results

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04933617

Jan 20th, 2023 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...

Patients with indolent lymphomas are at high risk of infections: experience from a Germ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833869
BMC Immunology; Lutz C, Feiten S et. al.

Jan 12th, 2023 - Patients with indolent B-cell non-Hodgkin lymphomas (B-NHLs) have an increased risk of infections which is caused by pathomechanisms of the diseases itself but also as a result of anti-tumor therapy. Especially the effects of anti-CD20 antibodies ...

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
https://clinicaltrials.gov/ct2/show/NCT01938001

Jan 9th, 2023 - Indolent lymphoma is a slow growing but incurable lymphoma which includes follicular lymphoma and marginal zone lymphoma. Follicular lymphoma and marginal zone lymphoma are cancers of the B lymphocyte, a type of white blood cell. Lenalidomide is a...

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma...
https://doi.org/10.1200/JCO.22.02403
Journal of Clinical Oncology : Official Journal of the Am... McLaughlin P, Grillo-López AJ et. al.

Jan 6th, 2023 - The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less imm...

Survival trends in young patients with Waldenström macroglobulinemia: Over five decades...
https://doi.org/10.1002/ajh.26807
American Journal of Hematology; Chohan KL, Paludo J et. al.

Jan 3rd, 2023 - Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, that predominately affects the elderly. We report the outcomes of young WM patients, evaluated over five decades, compared to their older counterparts, matched for the time of diagno...

see more →

Guidelines  1 results

SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma.
https://doi.org/10.1007/s12094-010-0592-7
Clinical & Translational Oncology : Official Publication ... Rodríguez-Abreu D, Llanos Muñoz M et. al.

Oct 27th, 2010 - Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin's lymphoma (NHL) in the Western world. FL constitutes the most frequent indolent lymphoma, well characterized by its clinical presentation related to nodal involvement and i...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  48 results

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04933617

Jan 20th, 2023 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
https://clinicaltrials.gov/ct2/show/NCT01938001

Jan 9th, 2023 - Indolent lymphoma is a slow growing but incurable lymphoma which includes follicular lymphoma and marginal zone lymphoma. Follicular lymphoma and marginal zone lymphoma are cancers of the B lymphocyte, a type of white blood cell. Lenalidomide is a...

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent ...
https://clinicaltrials.gov/ct2/show/NCT04431635

Dec 14th, 2022 - Patients with relapsed/refractory lymphoma generally have few if any curative options and demonstrate poor response rates to standard salvage therapies. Novel regimens utilizing molecular targets are needed to improve outcomes in this patient popu...

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02953509

Dec 9th, 2022 - The primary objectives of this study are: To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, ge...

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T) for Relapsed or Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05326243

Oct 26th, 2022 - Cluster of differentiation (CD) 19 chimeric antigen receptor T-cell (CAR-T) has been a very promising treatment option for multiple types of B-cell lymphoma. Kymriah® (tisagenlecleucel, Novartis) and Yescarta® (axicabtagene ciloleucel, Gilead) wer...

see more →

News  157 results

Loncastuximab Tesirine/Rituximab Elicits Promising Anti-Tumor Activity in Relapsed/Refractory DLBCL
https://www.onclive.com/view/loncastuximab-tesirine-rituximab-elicits-promising-anti-tumor-activity-in-relapsed-refractory-dlbcl

Oct 24th, 2022 - Loncastuximab tesirine-lpyl (Zynlonta) combined with rituximab (Rituxan) demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to data from p...

Dr. Orellana-Noia on the Patient Population of the POLARIX Trial in DLBCL
https://www.onclive.com/view/dr-orellana-noia-on-the-patient-population-of-the-polarix-trial-in-dlbcl

Sep 23rd, 2022 - Victor M. Orellana-Noia, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses the patient population of the phase 3 POLARIX trial (NCT03274492) in diffuse large B-cell lymphoma (DLB...

FDA Accepts sBLA for Polatuzumab Vedotin Plus R-CHP in Untreated DLBCL
https://www.onclive.com/view/fda-accepts-sbla-for-polatuzumab-vedotin-plus-r-chp-in-untreated-dlbcl

Aug 24th, 2022 - The FDA has accepted a supplemental biologics license application (sBLA) for the combination of polatuzumab vedotin-piiq (Polivy) and R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) as a treatment for patients with previ...

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
https://www.onclive.com/view/fda-approval-insights-liso-cel-in-second-line-relapsed-refractory-lbcl

Jul 28th, 2022 - Welcome to OncLive On Air®! I’m your host today, Caroline Seymour. OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital ...

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL
https://www.onclive.com/view/second-line-axi-cel-offers-a-practice-changing-indication-for-lbcl

Jun 29th, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...

see more →